ISB News

Participatory Medicine Q&A with Lee Hood

Genome Medicine featured ISB's Dr. Lee Hood in a series about participatory medicine.

Genome Medicine created a participatory medicine series, which was guest edited by Dr. Lee Hood, president of Institute for Systems Biology, and Dr. Charles Auffray, Founding Director of the European Institute for Systems Biology and Medicine. You can read the collection of articles on participatory medicine here. It includes an editorial "Participatory medicine: a driving force for revolutionizing healthcare" co-authored by Hood and Auffray that was published in December 2013.

Genome Medicine senior assistant editor, Andreia Cunha, also produced an accompanying podcast that features in interview with Hood. Listen to the podcast.

Read the Q&A with Lee Hood about participatory medicine that was featured in BioMed Central's Biome Magazine.

Excerpt:

How would you define participatory medicine?

Participatory medicine actually has many different components. I’d say, first of all, there is a big revolution coming in healthcare. That revolution is reflected in several different names: systems medicine, P4 medicine (predictive, preventive, personalized and participatory), or personalized medicine. In a sense, each of these names reflects variations on the theme of data-driven personalized medicine. This concept encompasses the idea that soon each patient will be surrounded by a virtual cloud of billions of data points and that we will have the computational analytics to integrate these data and reduce their enormous dimensionality to simple hypotheses about how to optimize wellness and minimize disease for each individual. — Dr. Lee Hood from a Genome Medicine Q&A

Recent Articles

  • Co-corresponding author and ISB President Dr. Jim Heath and co-lead author Dr. Yapeng Su.

    For Cancer Cells, There Is More Than One Path to Drug Resistance

    In findings published in the journal Nature Communications, researchers show that cancer cells can take more than one path to reach a drug-resistant cell state. These findings could have promising implications for the future of cancer care.

  • ISB researchers

    Unveiling the Guerrilla Warfare Tactics of Mycobacterium Tuberculosis

    ISB researchers have unveiled new insights on how Mycobacterium tuberculosis, the pathogen that causes tuberculosis, enters and exits a dormant state in human hosts. About a quarter of the world’s population has latent TB, so these important findings will enable and accelerate the discovery of more effective TB drugs.

  • Merck and ISB Collaborate to Understand and Treat SARS-CoV-2 Infection

    Merck is collaborating with ISB and its partners to analyze blood samples and nasal swabs from Swedish Medical Center patients with SARS-CoV-2. Blood samples will be examined using proteomic, metabolomic, transcriptomics and genetic techniques to evaluate the impact of infection on different organs, and to identify potential biomarkers to predict the risk of severe disease.